- Capital Cube•4 days ago
Categories: ETFs Yahoo Finance Click here to see latest analysis ETF’s with exposure to Aralez Pharmaceuticals, Inc. Here are 5 ETF’s with the largest exposure to ARZ-CA. Comparing the performance and risk of Aralez Pharmaceuticals, Inc. with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
- Zacks Small Cap Research•11 days agoAralez Pharmaceuticals (NASDAQ:ARLZ): Third Times a Charm! FDA Approves YOSPRALA®; Will Launch the First Week of October 2016
On September 15, 2016, Aralez Pharmaceuticals, Inc. (ARLZ) announced that the Food and Drug Administration (FDA) approved YOSPRALA® for patients who require aspirin for secondary prevention of cardiovascular and cerebrovascular events and who are at risk of developing aspirin associated gastric ulcers. YOSPRALA® is composed of a delayed-release aspirin (either 81 mg or 325 mg) and an immediate-release omeprazole (40 mg) intended for the secondary prevention of heart attack and stroke. For patients who have suffered a heart attack or stroke, taking daily aspirin has been shown to help prevent the occurrence a second heart attack or stroke.
- TheStreet.com•15 days ago
Aralez Pharmaceuticals (ARLZ) said on Thursday that its Yosprala drug for prevention of cardiovascular disease was approved by the FDA.
Aralez Pharmaceuticals Inc. (ARZ.TO)
Toronto - Toronto Delayed Price. Currency in CAD
|Day's Range||6.39 - 6.50|
|52wk Range||4.07 - 8.75|
|1y Target Est||N/A|
|P/E Ratio (ttm)||-3.80|
|Avg Vol (3m)||22,919|
|Dividend & Yield||N/A (N/A)|